FDA declines to approve Pain Therapeutics' opioid drug, shares plunge

The U.S. Food and Drug Administration declined to approve Pain Therapeutics Inc's abuse-deterrent opioid treatment Remoxy for the fourth time, sending the company's shares down 35 percent to a record low.